Mumbai: Drug maker Cadila Healthcare said on 30 August it has applied to Drug Controller General of India (DCGI) seeking approval for clinical trials of its novel drug candidate ‘ZYH7’ for treating disruption of lipids in the blood and related metabolic disorders.
An Investigational New Drug (IND) application seeking permission for clinical trials of its New Molecular Entity (NME) ‘ZYH7’ has been filed with the DCGI, Cadila informed the Bombay Stock Exchange.
Developed by scientists at Zydus Research Centre, the recent pre-clinical studies on ZYH7 came up with encouraging findings which indicate a novel molecule to treat dyslipidemia or disruption of lipids in the blood and associated metabolic disorders.
People with diabetes are at especially high risk for dyslipidema, particularly high triglyceride. levels and low HDL levels. dyslipidemia is also a key independent risk factor for cardiovascular disease (CVD), which is the largest therapeutic segment in the global pharmaceutical market.
Currently, the company has four INDs in various stages of clinical trials. These include NMEs like ZYH1, used for treating dyslipidemia, and ZYH, for treating pain and inflammation, which are undergoing Phase II trials. The other one is ZYO1 for treating obesity and is undergoing Phase I trials.